Tag Archives: Novartis

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, pricing, Strategy | Also tagged , , , , , , , | 6 Comments

European Commission Investigates J&J, Novartis

By Stephanie Sutton. The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules.
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , | Leave a comment

Merck and Novartis Down in Q3 Financial Reports

By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Posted in Deals, Global, Guest Blog, leadership | Also tagged , , , | Leave a comment

Will WHO Member States Pony Up for Neglected Diseases?

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. […]
Posted in Emerging Markets, Global, IP, leadership, Legal, Manufacturing, Market Access, pricing, R&D | Also tagged , , , , , , , , , | Leave a comment

Patent Filing to Drug Approval: A Difficult Journey Even for the Mighty

By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years. According to the law firm, only 129 “patent […]
Posted in Global, Guest Blog | Also tagged , | 1 Comment
  • Categories

  • Meta